The interim results of a phase 3 trial of Merck’s pulmonary arterial hypertension (PAH) treatment Winrevair were so ...

Russell Brand has been charged with rape, indecent assault, and sexual assault stemming from incidents with four women in the U.K. between 1999 to 2005. The Metropolitan Police announced the ...

Russell Brand was charged with multiple rape and assault charges by four women on April 4 Jeff Spicer/Getty Images Russell Brand is being charged with five counts of assault and rape charges ...

Russell Brand has been charged with rape, indecent assault and sexual assault by London’s Metropolitan Police. The charges relate to four separate women and incidents that took place between ...

Russell Brand has been charged with rape and two counts of sexual assault between 1999 and 2005. The Metropolitan Police say the 50-year-old comedian, actor and author has also been charged with ...

Several years ago, while preparing for one of our brand management classes at Dhaka University, we searched for a suitable example of a brand that significantly contributes to a country's GDP.

In the meantime, getting smart about tariffs, getting good expert advice and remaining flexible is the best that any retailer or brand can do.

The stock of Merck MRK has declined 19.2% in the past six months, losing almost $52 billion of its market value The numerous challenges plaguing the company resulted in the dilution of the stock ...

Russell Brand is facing rape and assault charges in London over alleged incidents with four separate women between 1999 and 2005. Per the BBC, the comedian has been charged with one count of rape ...

Merck has signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion, the latest in a series of deals U.S. drugmakers have recently signed with ...

Merck is planning layoffs in Pennsylvania as part of a multi-year plan to wind down operations at a manufacturing plant in the state. The pharma giant will cut 163 jobs at its Cherokee ...

With the CSF-1R inhibitor space heating up, Merck KGaA has gone all-in on pimicotinib, paying Abbisko Therapeutics $85 million to secure the global license to the drug. The German pharma ...